DelveInsight Business Research, LLP: Anal Cancer Market to Showcase Growth at a CAGR of 18% by 2034
Currently, several emerging therapies, such as retifanlimab, BMX-001, LCB84, KEYTRUDA (pembrolizumab), and others, are being evaluated in late-stage and mid-stage clinical trials. The successful